The University of Tartu is a classical university in the city of Tartu, Estonia. University of Tartu is the national university of Estonia; it is the biggest and highest-ranked university in Estonia. The University of Tartu is a member of the Coimbra Group and the Utrecht Network, and was established by King Gustavus Adolphus of Sweden in 1632, thus being one of the oldest universities in Northern Europe. Wikipedia.
University of Tartu and Tartu Health Care College | Date: 2015-03-03
A device for monitoring a treatment of posture of body parts in which a local mechanotherapeutic stimulus is applied includes an elastic material which is to be worn over the part of the body, a pressure regulating support, a pressure applicator and a pressure sensor. The support is fixed to the elastic material and passes over a region where mechanotherapeutic stimulus is to be applied. The sensor is rigidly attached to the pressure applicator and they are together received in a pocket. The sensor senses pressure and hence a stimulus applied to the part as a result of the tension in the support, the sensor being configured to output a signal indicative of the pressure applied, providing the opportunity to change the stimulus to within a given range based on the feedback from the sensor. A method for using the device is also disclosed.
Tallinn University of Technology and University of Tartu | Date: 2016-08-27
A tropomyosin receptor kinase (Trk) antagonist having a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is CH_(3), R2 is OCH_(3), R3 is SO_(2)N(CH_(3))_(2), and R4 is H; or R1 is CH_(3), R2 is OH, R3 is SO_(2)N(CH_(3))_(2), and R4 is H.
University of Tartu and Tartu Health Care College | Date: 2017-01-11
A method and device for monitoring a treatment of posture of different body parts in which a local mechanotherapeutic stimulus is applied to a subject (e.g. a human or animal). The device comprises an elastic material 1 which is to be worn over the part of the body, a pressure regulating support 4, a pressure applicator 7 and a pressure sensor 8. The support 4 is fixed to the elastic material 1 and passes over a region where mechanotherapeutic stimulus is to be applied and allows for tension in the support to be varied and to act on a convex rear face of the pressure applicator 7. The sensor 8 is rigidly attached to the pressure applicator 7 and they are together received in a pocket. The sensor senses pressure and hence a stimulus applied to the part as a result of the tension in the support, the sensor being configured to output a signal indicative of the pressure applied, providing the opportunity to change the stimulus to within a given range based on the feedback from the sensor.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-04-2016 | Award Amount: 9.71M | Year: 2017
The projects overall aim is to improve the health, development and quality of life of children and adults born very preterm (VPT, < 32 weeks of gestation) or very low birth weight (VLBW, < 1500g) approximately 50 000 births each year in Europe by establishing an ICT platform to integrate, harmonise and exploit the wealth of data from 20 European cohorts of VPT/VLBW children and adults and their families constituted from the early 1980s to the present, together with data from national registries. VPT/VLBW births have higher risks of cerebral palsy, visual and auditory deficits, impaired cognitive ability, psychiatric disorders and social problems than infants born at term and account for more than a third of the health and educational budgets for children. They may also face higher risks of non-communicable disease as they age. There is emerging evidence of reduced mental health, quality of life, partnering, family life and employment chances and wealth in adulthood. The platform will enable stratified sub-group analyses of sociodemographic and clinical characteristics, neonatal complications, and otherwise rare medical conditions that cannot be studied in national population cohorts. The broad temporal, geographic, cultural and health system diversity makes it possible to study the impact of socioeconomic and organisational contexts and determine the generalisability of outcomes for VPT/VLBW populations. The RECAP platform creates a value chain to promote research and innovation using population cohorts, beginning with the integration of VPT/VLBW cohorts to the translation and dissemination of new knowledge. It will be based on a sustainable governance framework, state-of-the art data management and sharing technologies, tools to strengthen research capacity, a hypothesis-driven research agenda and broad stakeholder participation, including researchers, clinicians, educators, policy makers and very preterm children and adults and their families.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: INFRADEV-03-2016-2017 | Award Amount: 3.30M | Year: 2017
Childrens health is a major societal challenge for Europe and the world, requiring development of paediatric medicines and treatments strategies based on evidence derived from clinical trials demonstrating efficacy and safety in infants and children, rather than on uncritical extrapolation from adult data (over 50 % of the medicines used for children had not been tested in this specific age group). Conducting clinical trials in children requires specific competences and infrastructure. ECRIN-ERIC (www.ecrin.org) is a generic infrastructure for multinational trial management, in any disease area. However it does not specifically address the paediatric needs in terms of trial management capacity. In its 2016 Roadmap, ESFRI suggested an upgrade of ECRIN to develop a common infrastructure for paediatric trial management through cooperation with the European Paediatric Clinical Trial Research Infrastructure (EPCTRI). The resulting PedCRIN project is also a unique opportunity to improve ECRIN business model and financial sustainability, attracting more industry-sponsored trials and more Member and Observer countries. PedCRIN builds on five work packages : project coordination (WP1); establishment of a strategy and upgrade of the governance and business plan, through a Sustainability Board jointly involving the scientific partners and the government representatives (WP2); development of tools specific for paediatric and neonatal trials (WP3) (methodology, outcome measures, adverse event reporting, bio-sample management, ethical and regulatory database, monitoring, quality and certification); operational support provided as transnational access to a few pilot trials to test the updated organisation and tools (WP4); communication targeting users communities (including industry), policymakers, patient and parents empowerment (WP5). Two other ESFRI-landmarks, BBMRI-ERIC and EATRIS ERIC, will contribute to PedCRIN.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: SCC-01-2015 | Award Amount: 32.20M | Year: 2016
SmartEnCitys main Objective is to develop a highly adaptable and replicable systemic approach towards urban transformation into sustainable, smart and resource-efficient urban environments in Europe through the integrated planning and implementation of measures aimed at improving energy efficiency in main consuming sectors in cities, while increasing their supply of renewable energy, and demonstrate its benefits. The underlying concept of the proposal is the Smart Zero Carbon City concept, where city carbon footprint and energy demand are kept to a minimum through the use of demand control technologies that save energy and promote raised awareness; energy supply is entirely renewable and clean; and local energy resources are intelligently managed by aware citizens, as well as coordinated public and private stakeholders. This approach will be firstly defined in detail, laid out and implemented in the three Lighthouse demonstrators (Vitoria-Gasteiz in Spain, Tartu in Estonia and Sonderborg in Denmark). The three cities will develop a number of coordinated actions aimed at: Significant demand reduction of the existing residential building stock through cost-effective low energy retrofitting actions at district scale. Increase in RES share of energy supply, through extensive leveraging of local potentials. Enhance the use of clean energy in urban mobility, both for citizens and goods, by means of extensive deployment of green vehicles and infrastructure. An extensive use of ICTs is planned to achieve integration and consistency in demo planning and implementation, and to enable further benefits and secure involvement of citizens. These actions will be aligned to city-specific Integrated Urban Plans (IUPs), and the process will be replicated in two Follower cities: Lecce, (Italy), and Asenovgrad (Bulgaria) to ensure adaptability and maximize the project impact. Additionally, a Smart Cities Network will be setup to support project replication at European scale.
Agency: European Commission | Branch: H2020 | Program: SGA-RIA | Phase: FETFLAGSHIP | Award Amount: 89.00M | Year: 2016
This project is the second in the series of EC-financed parts of the Graphene Flagship. The Graphene Flagship is a 10 year research and innovation endeavour with a total project cost of 1,000,000,000 euros, funded jointly by the European Commission and member states and associated countries. The first part of the Flagship was a 30-month Collaborative Project, Coordination and Support Action (CP-CSA) under the 7th framework program (2013-2016), while this and the following parts are implemented as Core Projects under the Horizon 2020 framework. The mission of the Graphene Flagship is to take graphene and related layered materials from a state of raw potential to a point where they can revolutionise multiple industries. This will bring a new dimension to future technology a faster, thinner, stronger, flexible, and broadband revolution. Our program will put Europe firmly at the heart of the process, with a manifold return on the EU investment, both in terms of technological innovation and economic growth. To realise this vision, we have brought together a larger European consortium with about 150 partners in 23 countries. The partners represent academia, research institutes and industries, which work closely together in 15 technical work packages and five supporting work packages covering the entire value chain from materials to components and systems. As time progresses, the centre of gravity of the Flagship moves towards applications, which is reflected in the increasing importance of the higher - system - levels of the value chain. In this first core project the main focus is on components and initial system level tasks. The first core project is divided into 4 divisions, which in turn comprise 3 to 5 work packages on related topics. A fifth, external division acts as a link to the parts of the Flagship that are funded by the member states and associated countries, or by other funding sources. This creates a collaborative framework for the entire Flagship.
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2016 | Award Amount: 1.30M | Year: 2017
Schizophrenia (SZ) is a severe mental disorder affecting more than 0.7% of the adult population. One of the most disabling and emotionally devastating illnesses known to man, SZ is also associated with considerable socioeconomic burden. In general, the chronic nature and the high degree of patient disability make SZ the fourth leading cause of disease burden across the globe with the management costs making up ~3% of the total healthcare budget in the Western countries. The situation is even direr in some regions, including northern Sweden and Finland, where relative prevalence of SZ exceeds two to three times corresponding national or regional averages. Poorly understood aetiology and limited diagnostic arsenal make it difficult to detect and treat SZ in a timely and efficient manner. This underscores a critical need for better understanding of the mechanisms underlying SZ and development of new diagnostic possibilities allowing its early detection, ideally prior to the onset of psychosis. The SZ_TEST will address these challenges by coordinating efforts with complementary areas of expertise in genetics, epigenetics, neurodevelopment, molecular psychiatry, clinical immunology and biotech R&D. The overarching hypothesis underlying our work is that genetic vulnerabilities, neurodevelopmental defects, exposure to pathogens, immune system status and specific lifestyle choices may compound the risk of SZ and that a systematic multivariate analysis of these factors should result in substantially improved diagnostic tools. SZ_TEST will work towards the development of molecular diagnostics tools for early detection of SZ, by using relevant cohorts of human subjects, unique animal and cell models, and combining unbiased high-throughput omic screens with knowledge-based candidate marker analyses. SZ_TEST training network is expected to have a major impact on improving the quality of life and reducing the health care costs in Europe and worldwide.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-22-2016 | Award Amount: 6.34M | Year: 2017
Next-Lab intends to change the educational landscape of science and technology education in Europe on a very large scale. The project offers a unique and extensive collection of interactive online (virtual and remote) laboratories that, through a process of mixing and re-use, can be straightforwardly and efficiently combined with dedicated support tools (learning apps) and multimedia material to truly form open, cloud-based, shareable educational resources with an embedded pedagogical structure. Next-Lab offers extensive opportunities for localisation and personalisation together with analytics facilities monitoring students progress and achievements. Next-Lab is designed to rely on full co-creation with users in combination with rapid development and testing cycles. Next-Lab builds on the highly successful (FP7) Go-Lab project that already offers online labs, inquiry learning apps, and authoring facilities for inquiry learning. To amplify the existing impact to the next-level innovation stage, Next-Lab extends the Go-Lab system with tools for the learning of 21st century skills, facilities for self- and peer-assessment and portfolio development, as well as opportunities to include learning by modeling. Next-Lab will cover secondary and also primary education, to ensure an early positive attitude towards science and technology and the continuous availability of innovative learning material throughout students school career. To guarantee long-term impact, Next-Lab also addresses the teachers of the future by its presence in pre-service teacher training programs throughout Europe. To evaluate its impact, Next-Lab combines usage data analysis techniques for very large-scale pilots with in-depth, qualitative, case-based, assessments. Next-Lab prepares for a following sustainable stage of the product. As it builds upon and extends existing networks of teachers, professional associations, and policymakers, the impact of Next-Lab will be massive.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: INFRASUPP-03-2016 | Award Amount: 992.25K | Year: 2017
The project aims at creating an EU-Africa e-Infrastructure, UBORA, for open source co-design of new solutions to face the current and future healthcare challenges of both continents, by exploiting networking, knowledge on rapid prototyping of new ideas and sharing of safety criteria and performance data. The e-infrastructure will foster advances in education and the development of innovative solutions in Biomedical Engineering (BME), both of which are flywheels for European and African economies. It is conceived as a virtual platform for generating, exchanging, improving and implementing creative ideas in BME underpinned by a solid safety assessment framework. Besides the provision of resources with designs, blueprints and support on safety assessment and harmonisation, specific sections for needs identification, project management, repositories and fund raising are also foreseen. UBORA (excellence in Swahili) brings together European and African Universities and their associated technological hubs (supporting biomedical prototyping laboratories and incubators), national and international policymakers and committed and credible stakeholders propelled by a series of Summer Schools and Competitions. In a nutshell, UBORA couples the open design philosophy with Europes leadership in quality control and safety assurance, guaranteeing better health and new opportunities for growth and innovation.